Emergent BioSolutions Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EBS research report →
Range $10 – $10
Price Chart
About the company
Emergent BioSolutions Inc. is a life sciences company dedicated to providing vital preparedness and response solutions for a wide range of public health threats (PHTs) across the United States. These threats encompass accidental, deliberate, and naturally occurring events, including chemical, biological, radiological, nuclear, and explosives (CBRNE) incidents, emerging infectious diseases, travel-related health risks, and acute emergency care situations.
- CEO
- Joseph C. Papa Jr.
- IPO
- 2006
- Employees
- 900
- HQ
- Gaithersburg, MD, US
Get TickerSpark's AI analysis on EBS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $259.65M
- P/E
- -1.12
- Fwd P/E
- 17.44
- PEG
- -0.06
- P/S
- 0.45
- P/B
- 0.92
- EV/EBITDA
- -5.30
- Div Yield
- 0.00%
- Gross Margin
- 41.60%
- Op Margin
- -25.96%
- Net Margin
- -40.16%
- ROE
- -61.33%
- ROIC
- -19.30%
Latest fiscal year · YoY change
- Revenue
- $742.90M-28.8%
- Gross Profit
- $350.60M-6.6%
- Op Income
- $110.20M
- Net Income
- $52.60M+127.6%
- EPS
- $0.98+127.2%
- OCF Growth
- +190.6%
- FCF Growth
- +338.0%
- 52W High
- $14.06
- 52W Low
- $4.36
- 50D MA
- $6.47
- 200D MA
- $7.61
- Beta
- 2.37
- RSI (14)
- 28
- Avg Volume
- 1.11M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Emergent BioSolutions posted a quarter in line with expectations, with lower year-over-year revenue but stronger margin outlook for 2026 as it continues restructuring and balance-sheet repair.· November 2, 2026
- Q3 revenue was $110 million, in line with guidance but down from $231 million a year ago due mainly to MCM delivery timing.
- Year-to-date revenue reached $500 million, adjusted EBITDA was $128 million, and operating cash flow was $122 million.
- Management raised full-year adjusted gross margin guidance to 45% to 47% and reaffirmed a focus on cost discipline and restructuring savings.
- The company expects about $40 million of annualized savings from August restructuring actions, with the initial benefit showing up in Q4 2026.
- Debt reduction continued: Emergent repurchased $75 million of bond principal and ended the quarter with $176 million of cash and $226 million of liquidity.
Third-quarter 2026 revenue was $110 million, versus $231 million in Q3 2025. Adjusted EBITDA was negative $5 million and adjusted gross margin was 28%; SG&A and R&D operating expenses were $56 million, including $8 million of restructuring costs, versus $52 million a year ago. Year-to-date, revenue was $500 million, adjusted EBITDA was $128 million with a 25% margin, adjusted gross margin was 49%, and operating cash flow was $122 million. Full-year 2026 guidance was updated to revenue of $600 million to $645 million, adjusted gross margin of 45% to 47%, and adjusted EBITDA of $110 million to $140 million. Management said MCM revenue should decline versus last year because of delivery timing, while commercial revenue is tracking toward the lower end of a 20% to 25% revenue decline versus 2025.
Joe Papa framed the quarter around Emergent’s multiyear transformation, emphasizing mission, quality, compliance, and selective growth. He said the company is focused on biodefense preparedness, naloxone access, and differentiated programs such as pan-Ebola therapy, TEMBEXA, Ebanga, and Raxibacumab, while also evaluating AI-related partnerships and preparedness efforts. His tone was constructive but cautious, with repeated emphasis on disciplined capital allocation and the need to keep improving execution.
Rich Lindahl said the quarter reflected continued execution on transformation priorities, including restructuring actions expected to drive about $40 million of annualized savings, with the first impact in Q4 2026. He highlighted balance-sheet progress, including repurchasing $75 million of unsecured bond principal for $68 million of cash, ending with $176 million of cash and $226 million of liquidity, and reducing gross debt to $514 million from $693 million a year ago. He also noted year-to-date operating cash flow of $122 million, gross debt down $354 million from year-end 2023, and net leverage stable at 2.4x trailing 12-month adjusted EBITDA.
Analysts focused on two main issues: the naloxone competitive landscape and the timing of delayed MCM orders. Joe Papa said NARCAN still has a market-leading position, demand remains strong because overdose deaths are still too high, and newer competitors have not yet had a major impact; he also said KLOXXADO provides a higher-dose option for tougher cases. On MCM timing, management said there is reasonable visibility with government customers, but some orders may slip into 2027, and that both U.S. and international timing variability is reflected in the full-year revenue range.
The positive case is that Emergent is still generating meaningful cash, improving its balance sheet, and raising gross margin guidance even after a weak comparison quarter. Management also pointed to ongoing demand for biodefense products, continued international diversification, and a leading position in naloxone with some stabilization in pricing.
The main risks are timing-related: MCM deliveries can slip between quarters and into 2027, and commercial naloxone revenue is still under pressure from competitive pricing and volume softness. Q3 adjusted EBITDA was negative, and full-year revenue is now expected to decline versus prior year in both MCM timing and commercial channel weakness.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 95.7%
- Shares Outstanding
- 51.42M
- Float Shares
- 49.19M
of shares held by institutions
201 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for EBS, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Stephen CohenHouse · TN09 | Sell | Dec 11, 24 | Filing → |
| Josh GottheimerHouse · NJ05 | Sell | Nov 5, 21 | Filing → |
| Josh GottheimerHouse · NJ05 | Buy | Oct 18, 21 | Filing → |
| Josh GottheimerHouse · NJ05 | Sell | Sep 15, 21 | Filing → |
| Josh GottheimerHouse · NJ05 | Sell | Feb 23, 21 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Nov 24, 20 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Jul 30, 20 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Jun 30, 20 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Jun 19, 20 | Filing → |
| Josh GottheimerHouse · NJ05 | Buy | Jun 26, 20 | Filing → |
| Josh GottheimerHouse · NJ05 | Buy | Jun 15, 20 | Filing → |
| Stephen CohenHouse · TN09 | Sell | Mar 26, 20 | Filing → |
| Stephen CohenHouse · TN09 | Sell | Aug 29, 19 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 5.17M | ▲ 453.04K |
| Vanguard Group Inc | 3.55M | ▲ 13.33K |
| American Century Companies Inc | 3.31M | ▲ 541.88K |
| State Street Corp | 2.71M | ▼ 216.05K |
| Dimensional Fund Advisors LP | 2.57M | ▼ 509.54K |
| Vanguard Capital Management LLC | 2.16M | ▼ 37.70K |
| Lsv Asset Management | 1.99M | ▲ 294.46K |
| Acadian Asset Management LLC | 1.93M | ▲ 589.49K |
| Millennium Management LLC | 1.88M | ▲ 809.38K |
| Oak Hill Advisors LP | 1.51M | ▲ 400.68K |
| Geode Capital Management, LLC | 1.27M | ▼ 66.08K |
| Vanguard Portfolio Management LLC | 1.17M | ▲ 144.96K |
Held by 212 ETFs
Biggest fund positions in EBS by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 7, 26 | DeGolyer Donald W | sell | 17,800 |
| Oct 1, 26 | Williams Paul Anthony | sell | 3,000 |
| Aug 5, 26 | Duatschek Stephanie | other | 0 |
| Aug 5, 26 | Duatschek Stephanie | other | 0 |
| Aug 5, 26 | Duatschek Stephanie | other | 0 |
| Aug 5, 26 | Duatschek Stephanie | other | 0 |
| Aug 5, 26 | Duatschek Stephanie | other | 0 |
| Aug 5, 26 | Duatschek Stephanie | other | 0 |
| Aug 5, 26 | Duatschek Stephanie | other | 0 |
| Aug 5, 26 | Duatschek Stephanie | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our EBS coverage
Recent articles, reports, and earnings notes.
No research on EBS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate EBS report →Asimov and Emergent Biosolutions Announce Cell Line Development Partnership to Advance Novel Antibodies Against Ebola
globenewswire.com · Nov 16
Emergent BioSolutions: A Turnaround Still Waiting For Consistent Execution
seekingalpha.com · Nov 6
Emergent BioSolutions Receives $22.3 Million Delivery Order Modification to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War
businesswire.com · Nov 4
Emergent BioSolutions: 3 Key Takeaways for Long-Term Investors
fool.com · Nov 3
Emergent BioSolutions Inc. (EBS) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 2
Emergent Biosolutions Q3 Earnings Call Highlights
marketbeat.com · Nov 2
Emergent Biosolutions Reports Third Quarter 2026 Financial Results
businesswire.com · Nov 2
Emergent BioSolutions Announces Retirement of Chief Financial Officer Richard S. Lindahl
businesswire.com · Oct 16
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.